Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Acute kidney injury (AKI) is a frequent and serious complication of hospitalization, occurring in up to 7% of all admissions and more than half of intensive care unit patients, with mortality rates still approaching 50–65%. Despite advances in understanding its molecular mechanisms, early diagnosis and targeted therapy remain limited. Current diagnostic markers, such as serum creatinine, detect only late functional impairment rather than early tubular damage. Liver-type fatty acid-binding protein (L-FABP), a 14-kDa cytoplasmic protein expressed in proximal tubular cells, is rapidly released in response to ischemia and oxidative stress. Urinary L-FABP has therefore emerged as a promising early biomarker of renal tubular injury in various clinical settings, including sepsis and cardiac surgery.
Objective: To evaluate urinary L-FABP's diagnostic and prognostic performance for AKI detection and adverse outcome prediction.
Methods: This prospective cohort study enrolled 42 adult patients at Al-Kasr Al-Ainy University Hospital: 14 with confirmed AKI (KDIGO criteria), 14 ICU at-risk patients, and 14 healthy controls. Urinary L-FABP levels were measured alongside standard renal markers, with follow-up at days 7 and 14.
L-FABP demonstrated dramatic stepwise elevation across groups (AKI: 142.0 ng/mg Cr; ICU: 40.9 ng/mg Cr; controls: 2.6 ng/mg Cr; all p<0.001). Multivariate regression identified L-FABP ≥200 ng/mg Cr as the strongest independent predictor of 30-day mortality (OR 15.6, 95% CI 1.8-135.2, p=0.013), surpassing APACHE II scores ≥20 (OR 8.9, p=0.041). Correlation analysis revealed robust associations between L-FABP and serum creatinine (r=0.742, p<0.001), eGFR (r=-0.738, p<0.001), ICU stay (r=0.687, p<0.001), and hospital stay (r=0.652, p<0.001). ROC analysis demonstrated L-FABP's superior diagnostic performance (AUC 0.949) compared to serum creatinine (AUC 0.888, p=0.032) and eGFR (AUC 0.888, p=0.035), with optimal cutoff 26.8 ng/mg Cr achieving 92.9% sensitivity and specificity. For adverse outcome prediction, L-FABP achieved AUC 0.792, significantly outperforming APACHE II (p=0.045), serum creatinine (p=0.018), and eGFR (p=0.008). Combined models showed enhanced performance: L-FABP + KDIGO + APACHE II achieved AUC 0.885. Finally ,the optimal cutoff of 62.8 ng/mg Cr provided balanced performance with 75% sensitivity and 81.3% specificity, yielding clinically meaningful positive and negative predictive values (81.8% and 74.3%, respectively). The cutoff analysis reveals strategic options for clinical implementation - lower thresholds (≥30.0 ng/mg Cr) maximize sensitivity for screening highrisk patients, while higher cutoffs (≥150.0 ng/mg Cr) provide perfect specificity for identifying patients with the highest risk.
Urinary L-FABP demonstrates superior diagnostic accuracy for AKI detection and independently predicts mortality and adverse outcomes. Its strong correlations with clinical parameters and superior performance over traditional markers support its integration into multimodal risk stratification algorithms for early AKI detection and prognostication in critically ill patients.
